A Randomized Phase 2 Non-comparative Study Of The Efficacy Of Pf-04691502 And Pf-05212384 In Patients With Recurrent Endometrial Cancer

Trial Profile

A Randomized Phase 2 Non-comparative Study Of The Efficacy Of Pf-04691502 And Pf-05212384 In Patients With Recurrent Endometrial Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Gedatolisib (Primary) ; PF 4691502 (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Dec 2016 This trial was completed in Poland (end date: 2015-12-25), according to European Clinical Trials Database.
    • 04 Oct 2016 This trial was completed in Spain (end date: 2015-12-25), according to European Clinical Trials Database.
    • 18 Apr 2016 Results published in the Gynecologic Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top